Literature DB >> 27422156

Cytokine and microbial profiles in relation to the clinical outcome following treatment of peri-implantitis.

Stefan Renvert1,2,3, Cecilia Widén1, Rutger G Persson1,4.   

Abstract

AIM: To study whether cytokine levels and bacterial counts in p atients with peri-implantitis reflect clinical treatment outcome following non-surgical management.
MATERIALS AND METHODS: Luminex magnet bead technology and checkerboard DNA-DNA hybridization were used to assess treatment outcome after treatment at the implant with the most severe peri-implantitis in 41 participants.
RESULTS: Study group mean age was 40.3 years (SD ± 9.9). Stable treatment outcome after 6 months (no further bone loss, probing pocket depth decrease ≥0.5 mm, no bleeding/suppuration) was identified in 9 of 41 (22%) participants. Peri-implant crevicular fluid (PICF) levels were also lower for Il-1β (P < 0.01), and with trends of lower cytokine levels in PICF for TNF-α (P = 0.071), PDGFBB (P = 0.071), as well as for VEGF (vascular endothelial growth factor) (P = 0.071), and bacterial counts for Actinomyces israelii, Aggregatibacter actonomycetemcomitans (Y4), Campylobacter gracilis, Echerichia coli, Fusobacterium periodonticum, Leptotrichia buccalis, Parvimonas micra, Staphylococcus haemolyticus, Streptococcus anginosus, and Tannerella forsythia. Increasing levels of IL-1 β and S. aureus (r2  = 0.856) were found only at implants with non-stable outcome. A reduction of PICF levels for selected cytokines and bacteria studied had a sensitivity of 0.77, and a specificity of 0.80 against the clinical outcome as gold standard. Data analysis failed to differences in treatments (PerioFlow® versus YAG: ER laser) for changes in the expression of cytokines and bacteria studied.
CONCLUSIONS: At 6 months, clinically stable treatment outcome of peri-implantitis is associated lower levels of putative pathogens total bacterial load with ≥30% reduction of IL1-β, L-6, and VEGF levels in PICF.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bacteria; dental implant; human; pro-inflammatory marker

Mesh:

Substances:

Year:  2016        PMID: 27422156     DOI: 10.1111/clr.12927

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  10 in total

Review 1.  Leptotrichia species in human infections II.

Authors:  Emenike R K Eribe; Ingar Olsen
Journal:  J Oral Microbiol       Date:  2017-09-15       Impact factor: 5.474

Review 2.  The Microbiome of Peri-Implantitis: A Systematic Review and Meta-Analysis.

Authors:  Philipp Sahrmann; Fabienne Gilli; Daniel B Wiedemeier; Thomas Attin; Patrick R Schmidlin; Lamprini Karygianni
Journal:  Microorganisms       Date:  2020-05-01

Review 3.  Peri-Implantitis Diagnosis and Prognosis Using Biomarkers in Peri-Implant Crevicular Fluid: A Narrative Review.

Authors:  Hatem Alassy; Praveen Parachuru; Larry Wolff
Journal:  Diagnostics (Basel)       Date:  2019-12-07

Review 4.  Biosensor and Lab-on-a-chip Biomarker-identifying Technologies for Oral and Periodontal Diseases.

Authors:  Larissa Steigmann; Shogo Maekawa; Corneliu Sima; Suncica Travan; Chin-Wei Wang; William V Giannobile
Journal:  Front Pharmacol       Date:  2020-11-09       Impact factor: 5.810

Review 5.  Immunological Aspects of Dental Implant Rejection.

Authors:  Milad Baseri; Faraz Radmand; Reyhaneh Hamedi; Mehdi Yousefi; Hossein Samadi Kafil
Journal:  Biomed Res Int       Date:  2020-12-09       Impact factor: 3.411

6.  Identification of Potential Genetic Biomarkers and Target Genes of Peri-Implantitis Using Bioinformatics Tools.

Authors:  Xiaogen Zhang; Zhifa Wang; Li Hu; Xiaoqing Shen; Chundong Liu
Journal:  Biomed Res Int       Date:  2021-12-11       Impact factor: 3.411

7.  Clinical, Microbiological, and Biochemical Impact of the Surgical Treatment of Peri-Implantitis-A Prospective Case Series.

Authors:  Fernando Luengo; Myroslav Solonko; Javier Sanz-Esporrín; Ignacio Sanz-Sánchez; David Herrera; Mariano Sanz
Journal:  J Clin Med       Date:  2022-08-11       Impact factor: 4.964

8.  Asperuloside Prevents Peri-Implantitis via Suppression of NF-κB and ERK1/2 on Rats.

Authors:  Xinge Wang; Xutao Chen; Zhaoxin Zhang; Ji Chen; Zeyang Ge; Shitou Huang; Hongbo Wei; Dehua Li
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-20

9.  Mangiferin alleviates experimental peri-implantitis via suppressing interleukin-6 production and Toll-like receptor 2 signaling pathway.

Authors:  Hao Li; Zhiyong Chen; Xinghua Zhong; Jiaquan Li; Wei Li
Journal:  J Orthop Surg Res       Date:  2019-10-17       Impact factor: 2.359

10.  Peri-Implant Surgical Treatment Downregulates the Expression of sTREM-1 and MMP-8 in Patients with Peri-Implantitis: A Prospective Study.

Authors:  Glaucia Schuindt Teixeira Neves; Gayathiri Elangovan; Mayla Kezy Silva Teixeira; João Martins de Mello-Neto; Santosh Kumar Tadakamadla; Eduardo José Veras Lourenço; Daniel Moraes Telles; Carlos Marcelo Figueredo
Journal:  Int J Environ Res Public Health       Date:  2022-03-18       Impact factor: 4.614

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.